[ TRANSACTION RECORD ]

GlaxoSmithKline Investment in Aiolos Bio — 2024

VERIFIED VECTOR ID: 001561 · tx-089
M SOURCE NODE — FUNDER
GlaxoSmithKline
Healthcare United Kingdom
$1,400,000,000
EQUITY
09/01/2024
Q DESTINATION NODE — RECIPIENT
Aiolos Bio
Company United States
Amount (USD)
$1.4B
Flow Type
EQUITY
Transaction Date
09/01/2024
Primary Source
View Filing ↗
Funder Profile [ M ]
Entity GlaxoSmithKline
AUM 100000
HQ Location United Kingdom
Sector Healthcare
Recipient Profile [ Q ]
Entity Aiolos Bio
Entity Type Company
Jurisdiction United States
Intelligence Note

GlaxoSmithKline (GSK) agreed to acquire Aiolos Bio for 1.4 billion dollars to gain access to a long-acting respiratory treatment for asthma. The transaction includes an initial payment and future milestone commitments to support clinical development. This deal underscores GSK’s strategy to bolster its specialty medicines pipeline through targeted biotech acquisitions.

Σ
Primary Forensic Source https://www.gsk.com/en-gb/media/press-releases/gsk-to-acquire-aiolos-bio/
✓ SOURCE LINKED